Strada Rivoltana Km 6/7
Rodano
20090
Italy
+39 02 95 231
Olon is an Italian company world leader in the Active Pharmaceutical Ingredients (APIs) production, using synthetic and biological processes for Generic market as well as in Contract Development and Manufacturing (CDMO).
With a 2020’s Turnover of 530 Mio$, OLON supplies 34 Chemical Intermediates and more than 295 APIs for the Generic market.
Thanks to all the 2.200 employees, and to highly qualified R&D team – more than 200 people – OLON can offer complete integrated packages and services to support the full development of APIs based on strong knowledge in both Chemical and Biological process, all of them under a full cGMP and regulatory coverage – holder of about 160 active US DMFs and 79 granted CoS.
Always considering human safety and environmental security, OLON handles different and not-common manufacturing process technologies, such as Fluorination, Carbonylation and Fermentation – combined with chemical synthesis to produce APIs for the majority, proteins, high-value small molecules & microorganisms (application in pharma), food, feed, and other bio-industrial markets.
Headquartered in Rodano (Milan, Italy), OLON has 11 manufacturing facilities - 8 located in Italy, 1 in Spain, 1 in USA and 1 in India, designed in compliance with the strictest international requirements, and 3 branch offices in Hamburg (Germany), Florham Park NJ (USA) and Shanghai (China).
The manufacturing sites are regularly inspected by the most important national and international Authorities, and regularly audited by our partners and customers. The facilities are FDA-inspected and self-identified under GDUFA.
Besides pharmaceutical certifications OLON complies with ISO standards (14001), has dedicated areas for food-grade manufacturing and complies with Kosher, Halal and within 2018-Q3 also with FSSC 22.000.
To be highlighted OLON’s growing cooperation with Universities: University of Milan (Italy), Milan Politecnico (Italy), University of Pavia (Italy), University of Murcia (Spain), and PROMIDIS (Milan University spin-off).
